Illumina Ordered to Pay Chinese Company $333 Million in Gene Sequencing Patent Case

May 6 (Reuters) – A Delaware jury on Friday ordered Illumina Inc (ILMN.O) to pay more than $333 million to a U.S. unit of Chinese genetic analysis firm BGI Genomics (300676.SZ) after found that Illumina’s DNA sequencing systems infringed two patents.

The jury also mentioned Illumina deliberately infringed patents and that three patents it alleged infringed BGI’s Complete Genomics unit were invalid.

BGI and Illumina have been embroiled in a global legal battle over their respective sequencing technologies.

Join now for FREE unlimited access to Reuters.com

Register

Illumina previously won $8 million from BGI in a jury verdict in San Francisco and a ban on U.S. sales of certain BGI products.

In the Delaware case, San Jose, Calif.-based Complete Genomics Inc, a subsidiary of BGI, challenged Illumina’s “two-channel” sequencing systems and kits for preparing DNA fragments for sequencing. to infringe its patent rights.

An Illumina spokesperson said the company plans to appeal and the verdict is not expected to affect its ability to supply customers.

A CGI attorney said the company was happy with the verdict.

Join now for FREE unlimited access to Reuters.com

Register

Reporting by Blake Brittain in Washington; Editing by David Gregorio

Our standards: The Thomson Reuters Trust Principles.

Comments are closed.